After Tencent and Byd Company Limited(002594) announced the anti-corruption fraud case, another listed company Hybio Pharmaceutical Co.Ltd(300199) (300199. SZ) in Shenzhen also announced the anti-corruption "results".
After a year of "blood exchange" of the senior management team, on the afternoon of January 25, 2022, Hybio Pharmaceutical Co.Ltd(300199) announced that it was learned from the public security and judicial organs that Yuan Jiancheng, the former director and President of the company, had been approved for arrest on suspicion of job-related crimes, and Zhu Wenfeng, the former director, Secretary of the board of directors and vice president, had been criminally detained on suspicion of job-related embezzlement. The matters involved were related to his tenure in the company.
Hybio Pharmaceutical Co.Ltd(300199) focusing on the polypeptide pharmaceutical industry chain in the subdivided field of the pharmaceutical industry, it is a national high-tech enterprise specializing in the R & D, production and sales of polypeptide drugs. It was IPO on the Shenzhen Stock Exchange in 2011. The company has great influence in the global polypeptide pharmaceutical industry, and the actual controller is the "three brothers" of Zeng shaogui family.
first financial reporter was informed exclusively from the insider. Judging from the current investigation, the 2 persons involved are independent cases, but there is a cross between them. The specific judicial organs are still under further investigation.
behind two executives in prison
Hybio Pharmaceutical Co.Ltd(300199) said in the annual report that the company is a Chinese polypeptide drug giant. Since its IPO in 2011, it has 24 polypeptide drugs, 9 new drug certificates and 17 clinical approvals. The company also said that "with its R & D advantages in the field of peptides, excellent product quality and the investment of international standardized production base, Hybio Pharmaceutical Co.Ltd(300199) has high recognition in China and international markets".
The origin of Yuan Jiancheng, who was arrested this time, and Hybio Pharmaceutical Co.Ltd(300199) should start from the start-up period of listed companies.
Yuan Jiancheng, 59, is an Hybio Pharmaceutical Co.Ltd(300199) "old man". He was a doctor in his early years and used to be the core R & D personnel of the company.
The prospectus disclosed yuan Jiancheng's experience in this listed company. Yuan Jiancheng participated in the research and development of Hybio Pharmaceutical Co.Ltd(300199) polypeptide drugs in the early stage, and the early research and development technology of polypeptide drugs of listed companies came from Shenzhen Hanyu Bioengineering Co., Ltd. ( Hybio Pharmaceutical Co.Ltd(300199) shareholder, hereinafter referred to as "Hanyu biology").
According to the prospectus, Hanyu biology was founded on June 5, 1998. At the beginning of its establishment, it had only three employees. Its main business is to develop a new class I polypeptide drug. Since the development technology of polypeptide drugs in China was very immature at that time, and the company did not have the conditions of technology, equipment and talents, many research works such as product synthesis, process research and quality research were entrusted to foreign companies, while pharmacodynamics, pharmacokinetics and toxicology were entrusted to Chinese companies.
The prospectus also said that through more than two years of operation and exploration, Hanyu biology found that this R & D model has many problems, such as high cost, slow progress and difficult foreign exchange. At the same time, the research and development of a class of new drugs also has huge technical and business risks. "The key is the lack of core competitiveness, that is, the support of technology and talents."
At the end of 2000, Hanyu biology decided to set up its own polypeptide drug research laboratory and introduced several technicians with a good foundation in organic chemical synthesis. On the one hand, it carried out the development of the original new class of polypeptide drugs, and on the other hand, it trained its own technical talents through the laboratory. At that time, Yuan Jiancheng studied in the United States.
"At that time, Yuan Jiancheng also continuously provided the latest foreign progress in the field of polypeptide drug technology in the United States to guide the research, development and operation of the laboratory." The prospectus said.
After Yuan Jiancheng returned to China in 2002, according to the research and experimental results of a class of new peptide drugs, he put forward the development idea of "supporting growth with short", that is, starting from generic drug production and customer peptide service, based on the establishment of a technical platform, master the core technology in the large-scale production of peptide drugs, and cultivate their own core technical talents. The scale of polypeptide laboratory has expanded rapidly, and the number of technicians has also expanded to more than 20.
According to the public resume, after returning home, Yuan Jiancheng served as the deputy director of the military Burn Research Institute of the Third Military Medical University, the vice president of Hanyu biology since 2004, and the president of Hybio Pharmaceutical Co.Ltd(300199) for a long time from 2007 to 2019. However, Yuan Jiancheng resigned in August 2019.
In addition to being the president of Hybio Pharmaceutical Co.Ltd(300199) for a long time, Yuan Jiancheng also holds equity in the company. According to the prospectus, Yuan Jiancheng directly holds 2.25% equity of Hanyu biology and 34.70% equity of Shenzhen Fengcheng Investment Co., Ltd. (hereinafter referred to as Fengcheng investment), the initiator of Hybio Pharmaceutical Co.Ltd(300199) . The shareholders of Fengcheng investment are 12 natural persons such as Zeng Shaobin, and the vast majority of the 12 natural person shareholders are middle and senior managers and other core personnel of the company.
The actual controllers of Hybio Pharmaceutical Co.Ltd(300199) are Zeng shaogui, Zeng Shaoqiang and Zeng Shaobin. They are brothers and all shareholders of the company. In total, they directly hold 66.257% of the shares of the company, accounting for an absolute controlling position. After years of development, the three Zeng brothers are still the actual controllers of listed companies.
According to the prospectus, Yuan Jiancheng and others have many years of experience in R & D, management and market promotion in the polypeptide drug industry, which has played a key role in the R & D and market grasp of the company's products. "If the above-mentioned core managers change significantly, it will have an adverse impact on the company's production and operation. Therefore, the company has the risk of relying on key managers."
The above-mentioned insider said that although yuan Jiancheng was not the core R & D director of Hybio Pharmaceutical Co.Ltd(300199) , he was also the core R & D personnel. "Zeng shaogui's family has always attached great importance to R & D talents, so they also respected yuan Jiancheng at the beginning. In addition to giving very high positions, they also allocated equity, but in the end, he embarked on the road of no return suspected of breaking the law." The person said.
for pharmaceutical enterprises and listed medical companies, the "mutiny" of core R & D personnel often puts the company in a passive position. According to the above insiders, after Yuan Jiancheng left office, he used his identity to report Hybio Pharmaceutical Co.Ltd(300199) to relevant departments, so the company had to take countermeasures.
In addition, Zhu Wenfeng performed his duties Hybio Pharmaceutical Co.Ltd(300199) in April 2016. In April 2016, Hybio Pharmaceutical Co.Ltd(300199) former Secretary Quan Heng resigned and Zhu Wenfeng replaced him as the company's secretary.
Zhu Wenfeng was a journalist in his early years. He once worked in Guangdong Guangsheng Asset Management Co., Ltd. and Shenzhen radio, film and television group. He successively served as a reporter and independent producer in Shenzhen radio, film and television group, managed three columns, and won the top ten producers (independent) of Shenzhen radio and Television Group in the past ten years. At that time, he served as a director, Secretary of the board of directors and vice president of the company.
Why are yuan Jiancheng and Zhu Wenfeng in prison? Hybio Pharmaceutical Co.Ltd(300199) did not disclose in detail. "More than 36 million yuan has been recovered from the job-related crime funds involved in Yuan Jiancheng, the former director and president.
” Hybio Pharmaceutical Co.Ltd(300199) only said that the above cases were found by the company's internal self-examination and reported to the public security organ. At present, the case is still under investigation by the public security judicial organ.
however, Hybio Pharmaceutical Co.Ltd(300199) insiders told reporters that the main reason why they reported the case to the public relations organ was that the above two people violated the relevant anti-corruption regulations of the company, and the board of directors had to "scrape bones and treat drugs" to protect the interests of all shareholders and investors.
It is worth noting that Yuan Jiancheng and Zhu Wenfeng, who were taken criminal coercive measures this time, were issued a warning letter by Shenzhen Securities Regulatory Bureau in 2021. On January 5, 2021, Hybio Pharmaceutical Co.Ltd(300199) disclosed the decision on administrative supervision measures of Shenzhen Securities Regulatory Bureau.
The on-site inspection of Hybio Pharmaceutical Co.Ltd(300199) by Shenzhen Securities Regulatory Bureau since August 2020 found that the operation of Hybio Pharmaceutical Co.Ltd(300199) board of directors and general meeting of shareholders was not standardized, and there were problems such as untimely information disclosure. There are problems in internal control and financial accounting, including the inconsistency between the batch number of some sold products and the batch number of returned products, resulting in confusion in inventory management and unable to accurately calculate the inventory age, which affects the accuracy of inventory falling price provision; There is no impairment test for capitalized R & D expenditure.
Shenzhen securities regulatory bureau pointed out that Yuan Jiancheng served as the director and President of Hybio Pharmaceutical Co.Ltd(300199) from November 2009 to August 2019 and was mainly responsible for the above problems. Zhu Wenfeng served as Hybio Pharmaceutical Co.Ltd(300199) vice president and Secretary of the board of directors in April 2016, and was mainly responsible for the above-mentioned problems of imperfect corporate governance and untimely information disclosure. Shenzhen Securities Regulatory Bureau has decided to take administrative supervision measures to issue warning letters to Yuan Jiancheng and Zhu Wenfeng.
internal "blood exchange" and rectification
The above Hybio Pharmaceutical Co.Ltd(300199) insiders said that the company will "zero tolerate" corruption, strictly strengthen the construction of internal control, further improve the level of governance, establish and improve the prevention mechanism, investigation mechanism and accountability system, resolutely crack down on illegal acts detrimental to the interests of listed companies, and "zero tolerate" corruption. At the same time, the company will continue to pay attention to the progress of the above matters, And perform the letter Phi obligations in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations.
The first financial reporter learned that over the past year, Hybio Pharmaceutical Co.Ltd(300199) has continued to strengthen internal control and "changed blood" and "cleaned" the original senior management team. Recently, the company announced a new candidate for the Secretary of the board of directors.
It was announced on January 25 that the board of directors of the company agreed to appoint Yang Di as the Secretary of the board of directors and Li Pingping as the representative of securities affairs. "Hanyu's anti-corruption this year has changed almost the entire original senior management team, including the securities department, with large-scale provision, and the stock price once reached a new low in history." Relevant people of Hanyu pharmaceutical told the first financial reporter that since 2021, the company has carried out strategic combing, followed the strategy of imitation and innovation combination, comprehensively accelerated the consistency evaluation, and promoted the new covid-19 polypeptide nasal spray of the Institute of Microbiology of the Chinese Academy of Sciences.
Hybio Pharmaceutical Co.Ltd(300199) revealed that in 2020, the company optimized the organizational structure of the R & D department, strengthened the technical force of the R & D center, and provided a solid guarantee for the maintenance of the company's R & D advantage. "The company attaches importance to R & D investment, maintains high R & D expenditure for a long time, and pays attention to the construction of R & D team."
After becoming the "champion" of the industry in the field of peptide drug R & D, Hybio Pharmaceutical Co.Ltd(300199) laid out covid-19 drug R & D in 2020. Since December 2020, the company's technical team has communicated and explored the research direction of polypeptide drugs with the Institute of Microbiology, Chinese Academy of Sciences.
In November 2021, Hybio Pharmaceutical Co.Ltd(300199) announced that to help New Coronavirus's current epidemic prevention and control, based on the technical exchange and cooperation between the company and the Institute of Microbiology of China Academy of Sciences in recent years, the two sides are going to cooperate in developing New Coronavirus polypeptide nasal spray drug. "COVID-19" At that time, academicians of the Chinese Academy of Sciences and researchers of the Institute of Microbiology of the Chinese Academy of Sciences appeared in the form of Gaofu video to participate in the signing of the contract between the two sides.
Hybio Pharmaceutical Co.Ltd(300199) said, the Chinese Academy of Sciences Micro Research Institute intends to "6 kinds of polypeptide sequences in the patent application technology (patent application number: 202110939740.1) of a kind of anti New Coronavirus peptide and its application", licensed by the global exclusive license to Hybio Pharmaceutical Co.Ltd(300199) , the total amount of the project is 65 million yuan.
Some time ago, the stock price of Hybio Pharmaceutical Co.Ltd(300199) rose sharply and attracted the attention of investors. Hybio Pharmaceutical Co.Ltd(300199) issued a risk warning, said the company and China Academy of Sciences microbiology Institute to develop New Coronavirus polypeptide nasal spray drug, follow-up also need to carry out COVID-19 virus and its variants live poison experiment, pre clinical research, clinical research, pharmaceutical research and marketing and other links, there is no clinical progress and effectiveness of the risk of the expected.
However, on January 25, Hybio Pharmaceutical Co.Ltd(300199) replied to investors on the investor interaction platform that the company's nasal spray project had urgently completed the joint application of relevant patents China and international (PCT patents) on December 31, 2021, "In order to speed up the implementation of the project, the covid-19 polypeptide nasal spray drug project team has arranged and implemented overtime during the Spring Festival, and has been doing relevant work for the large-scale production of API, preparation research, clinical research and subsequent industrialization."
As of the closing on January 15, Hybio Pharmaceutical Co.Ltd(300199) closed at 13.53 yuan, down 17.95%, with a total market value of 12.406 billion yuan.
